Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves

被引:52
作者
Landoni, MF
Lees, P
机构
[1] Department of Veterinary Basic Sciences, Royal Veterinary College, Hawkshead Campus, Hatfield, Hertfordshire
关键词
PK/PD modelling; ketoprofen; enantiomers; calves; NSAIDs; chirality;
D O I
10.1002/chir.530070806
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmacokinetics (PK) and pharmacodynamics (PD) of (S)- and (R)-ketoprofen (KTP) enantiomers were studied in calves after intravenous administration of each enantiomer at a dose of 1.5 mg/kg. Pharmacodynamic properties were evaluated using a model of acute inflammation, comprising subcutaneously implanted tissue cages stimulated by intracaveal injection of carrageenan. Chiral inversion of(R)-KTP to the (S)-antipode occurred. The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h. The calculated extent of inversion was 31 +/- 7%. The R:S ratio in inflammatory exudate was of the order 3:1 at all the sampling times and the ratio in transudate was approximately 2:1 for 6 h, declining to 1:1 at 30 h. Only (S)-KTP was detected in biological fluids after administration of this enantiomer. Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer. Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode. For (R)-KTP effects obtained were considered as a hybrid, since they potentially reflect the actions of both enantiomers. Concentrations of LTB(4) and the cytokines interleukin-1, interleukin-6, and tumor necrosis factor alpha, in exudate were not significantly affected by either (R)- or (S)-KTP treatments. Inhibition of ex vivo thromboxane B-2 (TxB(2)) synthesis, exudate prostaglandin E(2) (PGE(2)) synthesis, beta-glucuronidase release (beta-glu), and bradykinin-induced skin swelling was significant in both treated groups. PK/PD modelling was applied to the (S)-KTP treatment only. EC(50) values for inhibition of serum TxB(2), exudate PGE(2) and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 mu g/ml, respectively. It is concluded that the low EC(50) values for inhibition of TxB(2) and PGE(2) by (S)-KTP are likely to explain the effects produced by (R)-KTP administration, since concentrations of (S)-KTP in exudate of these calves following chiral inversion were at least 5 times higher than the EC(50) at all sampling times. The data for beta-glu and bradykinin-induced swelling inhibition indicate possible inhibitory actions of (R)-KTP as well as (S)-KTP. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:586 / 597
页数:12
相关论文
共 52 条
[21]   RE-EXAMINATION AND FURTHER DEVELOPMENT OF A PRECISE AND RAPID DYE METHOD FOR MEASURING CELL-GROWTH CELL KILL [J].
HANSEN, MB ;
NIELSEN, SE ;
BERG, K .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 119 (02) :203-210
[22]   THE INFLUENCE OF RENAL-FUNCTION ON THE ENANTIOSELECTIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF KETOPROFEN IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
HAYBALL, PJ ;
NATION, RL ;
BOCHNER, F ;
SANSOM, LN ;
AHERN, MJ ;
SMITH, MD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (03) :185-193
[23]   PLASMA-PROTEIN BINDING OF KETOPROFEN ENANTIOMERS IN MAN - METHOD DEVELOPMENT AND ITS APPLICATION [J].
HAYBALL, PJ ;
NATION, RL ;
BOCHNER, F ;
NEWTON, JL ;
MASSYWESTROPP, RA ;
HAMON, DPG .
CHIRALITY, 1991, 3 (06) :460-466
[24]   ENANTIOSELECTIVE PHARMACODYNAMICS OF THE NONSTEROIDAL ANTIINFLAMMATORY DRUG KETOPROFEN - INVITRO INHIBITION OF HUMAN PLATELET CYCLOOXYGENASE ACTIVITY [J].
HAYBALL, PJ ;
NATION, RL ;
BOCHNER, F .
CHIRALITY, 1992, 4 (08) :484-487
[25]   FUNCTIONAL DISCRIMINATION BETWEEN INTERLEUKIN-6 AND INTERLEUKIN-1 [J].
HELLE, M ;
BOEIJE, L ;
AARDEN, LA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (10) :1535-1540
[26]   TISSUE-CAGE MODEL FOR THE COLLECTION OF INFLAMMATORY EXUDATE IN PONIES [J].
HIGGINS, AJ ;
LEES, P ;
WRIGHT, JA .
RESEARCH IN VETERINARY SCIENCE, 1984, 36 (03) :284-289
[27]   KINETICS OF PHARMACOLOGIC RESPONSE [J].
HOLFORD, NHG ;
SHEINER, LB .
PHARMACOLOGY & THERAPEUTICS, 1982, 16 (02) :143-166
[28]   UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[29]  
IWAKAWA S, 1991, DRUG METAB DISPOS, V19, P717
[30]   KETOPROFEN PHARMACOKINETICS IN HUMANS - EVIDENCE OF ENANTIOMERIC INVERSION AND LACK OF INTERACTION [J].
JAMALI, F ;
RUSSELL, AS ;
FOSTER, RT ;
LEMKO, C .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (05) :460-461